Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness

(2009) Ahlame Saidi et al.   INTERNATIONAL JOURNAL OF CANCER

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy

(2008) E. R. Smith et al.   CLINICAL CANCER RESEARCH

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Time course of imaging changes of GBM during extended bevacizumab treatment

(2008) Suchitra Ananthnarayan et al.   JOURNAL OF NEURO-ONCOLOGY

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

(2008) Ashwatha Narayana et al.   JOURNAL OF NEUROSURGERY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme—improvement over available therapy?

(2008) Sajeel Chowdhary et al.   Nature clinical practice. Neurology